AUTL Autolus Therapeutics PLC

4.11

0.03 (0.74%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Name	Symbol	Market	Type
Autolus Therapeutics PLC	NASDAQ:AUTL	NASDAQ	Depository Receipt

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.03	0.74%	4.11	4.00	4.24	4.145	3.99	4.09	2,745,490	01:00:00

Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023

15/02/2023 12:00pm

GlobeNewswire Inc.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart

From Apr 2022 to Apr 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2022 financial results and operational highlights before open of U.S. markets on Tuesday, March 7, 2023.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com

Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com